WILMINGTON, Del., March 04, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating Five Prime Therapeutics, Inc. (“Five Prime”) (NASDAQ GS: FPRX) regarding possible breaches of fiduciary duties and other violations of law related to Five Prime’s agreement to be acquired by Amgen Inc. (“Amgen”) (NASDAQ GS: AMGN). Under the terms of the agreement, Five Prime’s shareholders will receive $38.00 in cash per share.
To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-five-prime-therapeutics-inc.
You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or email@example.com.
Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.
Attorney advertising. Prior results do not guarantee a similar outcome.